Get started
Author

Yelei Guo

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
2018 · Yao Wang, Meixia Chen, et al. · OncoImmunology · 341
PDF
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
2016 · Chun-Meng Wang, Zhi-Qiang Wu, et al. · Clinical Cancer Research · 335
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
2020 · Hanren Dai, Zhiqiang Wu, et al. · Journal of Hematology & Oncology · 334
PDF
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
2017 · Kaichao Feng, Yang Liu, et al. · Protein & Cell · 331
PDF
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
2016 · Kaichao Feng, Yelei Guo, et al. · Science China Life Sciences · 297
PDF
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
2020 · Chuan Tong, Yajing Zhang, et al. · Blood · 279
PDF
Infusion of Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetic Rats
2012 · Yiling Si, Yali Zhao, et al. · Diabetes · 273
Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
2017 · Yelei Guo, Kaichao Feng, et al. · Clinical Cancer Research · 271
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
2017 · Kai-chao Feng, Ye-lei Guo, et al. · Journal of Hematology & Oncology · 246
PDF
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
2021 · Yao Wang, Chuan Tong, et al. · Nature Communications · 241
PDF
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
2014 · Yao Wang, Wen-ying Zhang, et al. · Clinical Immunology · 197
Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
2020 · Hanren Dai, Chuan Tong, et al. · OncoImmunology · 182
PDF
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
2020 · Yang Liu, Yelei Guo, et al. · Cytotherapy · 179
PDF
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
2015 · Hanren Dai, Wenying Zhang, et al. · OncoImmunology · 168
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
2016 · Wen-ying Zhang, Yao Wang, et al. · Signal Transduction and Targeted Therapy · 136
PDF
Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
2017 · Yanjing Song, Chuan Tong, et al. · Protein & Cell · 112
PDF
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
2021 · Yajing Zhang, Yao Wang, et al. · Leukemia · 109
PDF
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
2019 · Jianshu Wei, Can Luo, et al. · Journal for ImmunoTherapy of Cancer · 107
PDF
Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo
2013 · Jianhua Huang, Chonghui Li, et al. · Clinical Immunology · 103
Clinical development of CAR T cell therapy in China: 2020 update
2020 · Jianshu Wei, Yelei Guo, et al. · Cellular and Molecular Immunology · 90
PDF
Cytokine-induced killer (CIK) cells: from basic research to clinical translation
2015 · Yelei Guo, Weidong Han · 癌症：英文版 · 85
PDF
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
2017 · Zhenguang Wang, Yelei Guo, et al. · Protein & Cell · 83
PDF
Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
2023 · Yao Wang, Chuan Tong, et al. · Signal Transduction and Targeted Therapy · 78
PDF
CD58 loss in tumor cells confers functional impairment of CAR T cells
2022 · Xin Yan, Deyun Chen, et al. · Blood Advances · 77
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
2016 · Bo Cai, Mei Guo, et al. · Journal of Hematology & Oncology · 66
PDF
Works count: 67
Citation count: 5,224
H-index: 34
I10-index: 37
Year
Topic
Type